As shown in Figure 11, the mRNA expression levels of AKT1, EGFR, GSK3B, JAK3, MAPK1, MAPK3, MDM2, PIK3CA, and SRC were increased in the TGF-β1-stimulated group, while administration of 0.1–10 μg/mL ZBM resulted in various degrees of improvement in these expression levels, indicating that ZBM inhibited IPF partially by regulating the expression levels of these targets and that the systematic analysis strategy based on network pharmacology was reliable. The gene discussed is MDM2; the disease is idiopathic pulmonary fibrosis.